APTARGROUP, INC.

AptarGroup maintains a debt-to-equity ratio of 0.5, indicating a balanced capital structure with moderate leverage. The company's liquidity position is characterized by a current ratio of 1.62, suggesting it can cover short-term obligations with a reasonable margin of safety. However, net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 14.72% and a return on assets (ROA) of 7.48%, both exceeding the industry median for the Non-Paper Containers & Packaging sector. These figures suggest strong asset utilization and profitability relative to its peers. The operating margin of 13.27% (calculated from operating income of $501.04 million on revenue of $3.78 billion) is also above the sector median, indicating efficient cost management. The company's revenue is distributed across three segments: Pharma, Beauty, and Closures. The Pharma segment, which supplies nasal drug delivery spray pumps and metered dose inhaler valves, is a key growth driver. The Beauty segment serves the fragrance, color cosmetics, and personal care markets, while the Closures segment provides dispensing and non-dispensing solutions. Revenue concentration is not explicitly disclosed, but the company's diversified end markets suggest a moderate level of geographic and segment diversification. AptarGroup's growth trajectory is supported by a strategic focus on organic growth in high-growth regions and acquisitions. The company's FY2025 revenue of $3.78 billion reflects a strong performance, and the outlook for the next fiscal year indicates continued growth. The company's capital expenditure of $270.42 million in FY2025 supports its expansion and technological innovation. Risk factors include medium liquidity risk due to the negative net cash position and medium dilution risk, as indicated by the risk assessment. The company's free cash flow of $299.58 million provides some buffer, but the short-term debt of $183.95 million and long-term debt of $1.14 billion could pose challenges if cash flow volatility increases. The risk assessment also notes potential dilution from offerings or equity issuance. Recent events include the adoption of new guidance in the fourth quarter of 2024, which affects income tax disclosures. The company is also expanding its digital health solutions across various therapeutic areas, including pulmonary, oncology, and diabetes. These developments align with its strategy to strengthen its position in drug delivery technologies.